NASDAQ NMS - GLOBAL MARKET · KRYS
-0.95% · -$3.05 · Vol 313.5K
Krystal Biotech Inc

Krystal Biotech Inc

Biotechnology
$318.50

Veridion Score

Loading
Score loading…
Veridion Score History · 90D

Composite trend over time

LOADING HISTORY…
REFRESHES DAILY
AI Analysis
Sovereign

Why is KRYS moving today?

Sovereign unlock connects news, insider activity, analyst moves, and live price action.
About Krystal Biotech Inc
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Founded
Listed
2017
Employees
295
HQ
US

Krystal Biotech Inc is an integrated, commercial-stage biotechnology company focused on the discovery, development, manufacturing, and commercialization of genetic medicines to treat diseases with high unmet medical needs. The company uses its patented HSV-1-based gene therapy platform to create vectors that deliver therapeutic transgenes to target cells. It possesses exclusive rights to develop, manufacture, and commercialize VYJUVEK internationally. The company operates as one operating segment focused on pharmaceutical products and manufactures, markets, and sells VYJUVEK in the United States and markets and sells VYJUVEK in the European Union, and Japan.

Key statistics

Real vendor fields plus Veridion-computed history. Missing fields stay blank.

Open
$331.49
Day high
$331.49
Day low
$316.54
Previous close
$321.55
52W high
$331.49
-3.92% from high
52W low
$312.41
32% of range
Market cap
$9.4B
P/E
EPS
Dividend yield
Beta
Shares out
29.5M
Float
Volume
313.5K
Avg volume
VWAP
$321.76
Next earnings
Price history computed in-house
1W
+1.95%
1M
+1.95%
3M
+1.95%
1Y
+1.95%
YTD
+1.95%
SMA 50 $318.89 · below
SMA 200 $318.89 · below
52W position 32%
Veridion warehouse edge

Warehouse intelligence for KRYS.

Disclosure-sourced lobbying and contract detail remains attributed in the full panels below.
Data ledger
Quote and day range
Refresh interval: 30 seconds
Source: Market data
Veridion Score
Coverage building
Chart and risk context
Daily bars with no missing-bar fill
Source: Market data
News and filings
Refresh intervals shown inside each panel
Source: Market news and federal filings
Financials
Loading quarterly statements…
SEC Form 4 ledger

KRYS insider activity

Krystal Biotech Inc

Score
Coverage building
Pressure
Net selling
Filings
152
Buys / sells
3 / 149
Net value
-$110.5M
Insiders
6
Named filers
KS
Krishnan Suma
Insider
Leadership
KS
Krishnan Krish S
Insider
Leadership
TC
Thomas John Charles
Insider
Leadership
Cluster

No multi-insider buying cluster in the last 90 days

Net pressure

Net selling: -$110.5M across loaded Form 4 rows.

Convergence not established

Loaded official disclosures do not show all three sources aligned on this ticker.

Filing dateTrade dateInsiderTitleTypePriceQtyOwnedValueReceipt
2026-06-052026-06-04Krishnan SumaInsidersell$311.652401,378,155$75KSEC Form 4
2026-06-052026-06-04Krishnan SumaInsidersell$310.942,0391,378,395$634KSEC Form 4
2026-06-052026-06-04Krishnan SumaInsidersell$309.952,8011,380,434$868KSEC Form 4
2026-06-052026-06-04Krishnan SumaInsidersell$308.893,8031,383,235$1.2MSEC Form 4
2026-06-052026-06-04Krishnan SumaInsidersell$307.8112,7291,387,038$3.9MSEC Form 4
Full Form 4 history requires Sovereign

Showing 5 recent rows. Sovereign unlocks 147 additional rows, full sorting, and the named-filer history.

Upgrade to Sovereign · $25/mo
Source: SEC EDGAR Form 4. Rows with missing price or quantity are excluded rather than zero-filled.Methodology
Congress · 90D
Loading PTR filings…
Federal contracts

KRYS contract awards, year to date.

Public federal awards linked to this ticker.

Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for KRYS in this window.
Lobbying spend

KRYS lobbying filings, year to date.

Registered lobbying filings matched to Krystal Biotech Inc.

Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for KRYS in this window.
Latest news · KRYS
Refresh interval: 5 minutes · Source: Market news insights
Loading articles…
Analyst ratings
Sovereign unlock shows live analyst consensus for KRYS.
Options
Sovereign unlock shows live options positioning for KRYS.
Weekly Veridion brief

Rating changes, public disclosure activity, methodology notes, and product updates. One email per week. No advertising list resale.